---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-091799"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:21:19.779070+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Olema Q2 net loss $30.4M; cash $239.1M; palazestrant combo shows 85% CBR

## Summary
- Net loss for Q2 2024 was $30.4M vs $20.1M in Q2 2023, driven by increased R&D spending on late-stage trials.
- Cash, cash equivalents and marketable securities of $239.1M as of June 30, 2024.
- Interim Phase 1b/2 data for palazestrant + ribociclib showed 85% clinical benefit rate in 13 evaluable patients.
- IND for KAT6 inhibitor OP-3136 expected to be filed with FDA in late 2024; pre-clinical data in Q4.
- Plan to initiate Phase 1b/2 study of palazestrant + everolimus in Q3 2024.

## SEC filing metadata
- accession: 0000950170-24-091799
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000095017024091799/0000950170-24-091799-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000095017024091799/olma-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-091799
- JSON: https://secwatch.observer/filing/0000950170-24-091799.json
- Plain text: https://secwatch.observer/filing/0000950170-24-091799.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.